Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ergomed plc
US FDA advisory panel feels there could be a place for Intarcia’s exenatide drug-device combo – if the company is willing to put in the work.
The US FDA is free from the need to reconsider Accelerated Approvals in a formal hearing in front of an advisory committee. But now the agency is now trying that approach to hear an appeal of a rejected application.
The Boston biotech raises series A cash and succeeds Intarcia as the sponsor of the GLP-1 drug/device combination product for type 2 diabetes, subject of two FDA complete response letters.
Private Company Edition: The amount of venture capital investment in biopharma companies has shrunk from quarter to quarter, but the average deal size remained high until the third quarter. Larger rounds from Treeline, Odyssey and Neumora offset a plethora of smaller VC financings early in Q4.
- Contract Research Organization-CRO
- Large Molecule
- Other Names / Subsidiaries
- Ashfield Pharmacovigilance
- Ergomed Group
- Haemostatix Limited
- PSR Group BV
- MS Clinical Services
- MedSource Technologies Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.